Clinical tests of the novel small-molecule inhibitor of p38α MAPK, VX-702, have resulted in an all-too-familiar outcome: modest clinical efficacy and transient inhibition of inflammatory markers. Why have p38α inhibitors failed, and what can we learn about the regulation of signal transduction pathways in inflammatory arthritis?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The protein tyrosine kinase SYK regulates the alternative p38 activation in liver during acute liver inflammation
Scientific Reports Open Access 28 November 2019
-
Differential regulation of anti-inflammatory genes by p38 MAP kinase and MAP kinase kinase 6
Journal of Inflammation Open Access 16 May 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schett, G., Zwerina, J. & Firestein, G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann. Rheum. Dis. 67, 909–916 (2008).
Damjanov, N., Kauffman, R. S. & Spencer-Green, G. T. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 60, 1232–1241 (2009).
Genovese, M. C. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 60, 317–320 (2009).
Cohen, S. B. et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum. 60, 335–344 (2009).
Ding, C. Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Curr. Opin. Investig. Drugs 7, 1020–1025 (2006).
Gruenbaum, L. M. et al. Inhibition of pro-inflammatory cytokine production by the dual p38/JNK2 inhibitor BIRB796 correlates with the inhibition of p38 signaling. Biochem. Pharmacol. 77, 422–432 (2009).
Boyle, D. L. et al. Regulation of peripheral inflammation by spinal p38 MAP kinase in rats. PLoS Med. 3, e338 (2006).
Firestein, G. S. Rheumatoid arthritis in a mouse? Nat. Clin. Pract. Rheumatol. 5, 1 (2009).
Hegen, M., Keith, J. C. Jr, Collins, M. & Nickerson-Nutter, C. L. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann. Rheum. Dis. 67, 1505–1515 (2008).
Hueber, A. & McInnes, I. Is spleen tyrosine kinase inhibition an effective therapy for patients with RA? Nat. Clin. Pract. Rheumatol. 5, 130–131 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Sweeney, S. The as-yet unfulfilled promise of p38 MAPK inhibitors. Nat Rev Rheumatol 5, 475–477 (2009). https://doi.org/10.1038/nrrheum.2009.171
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2009.171
This article is cited by
-
The protein tyrosine kinase SYK regulates the alternative p38 activation in liver during acute liver inflammation
Scientific Reports (2019)
-
Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches
Clinical Reviews in Allergy & Immunology (2018)
-
Differential regulation of anti-inflammatory genes by p38 MAP kinase and MAP kinase kinase 6
Journal of Inflammation (2014)
-
Role of p38 inhibition in cardiac ischemia/reperfusion injury
European Journal of Clinical Pharmacology (2012)
